iCAD Expands Executive Leadership with Appointment of Mark Koeniguer as Chief Commercial Officer
iCAD (NASDAQ: ICAD) has appointed Mark Koeniguer as Chief Commercial Officer (CCO) to spearhead global growth initiatives. Koeniguer, who brings over 30 years of experience in MedTech, AI, and digital health, will oversee commercial sales teams, partnerships, operations, and customer success.
Most recently as CEO of ScreenPoint Medical, Koeniguer achieved a 400% increase in annual recurring revenue and launched two FDA-cleared products. His previous executive roles include positions at Riverain Technologies, Volpara Health, R2 Technology, Stereotaxis, and GE Healthcare.
In his new role at iCAD, a provider of AI-powered breast health solutions, Koeniguer will focus on revenue growth across North America and globally, leveraging his extensive experience in the medical imaging field and software as a medical device (SaMD) space.
iCAD (NASDAQ: ICAD) ha nominato Mark Koeniguer come Chief Commercial Officer (CCO) per guidare le iniziative di crescita globale. Koeniguer, che porta con sé oltre 30 anni di esperienza nel MedTech, nell'AI e nella salute digitale, supervisionerà i team di vendita commerciali, le partnership, le operazioni e il successo del cliente.
Recentemente, come CEO di ScreenPoint Medical, Koeniguer ha ottenuto un aumento del 400% nel fatturato annuale ricorrente e ha lanciato due prodotti approvati dalla FDA. Le sue precedenti esperienze dirigenziali includono ruoli presso Riverain Technologies, Volpara Health, R2 Technology, Stereotaxis e GE Healthcare.
Nel suo nuovo ruolo in iCAD, fornitore di soluzioni per la salute del seno potenziate dall'AI, Koeniguer si concentrerà sulla crescita dei ricavi in Nord America e a livello globale, sfruttando la sua vasta esperienza nel campo dell'imaging medico e nello spazio dei software come dispositivo medico (SaMD).
iCAD (NASDAQ: ICAD) ha nombrado a Mark Koeniguer como Chief Commercial Officer (CCO) para liderar las iniciativas de crecimiento global. Koeniguer, quien aporta más de 30 años de experiencia en MedTech, IA y salud digital, supervisará los equipos de ventas comerciales, las asociaciones, las operaciones y el éxito del cliente.
Recientemente, como CEO de ScreenPoint Medical, Koeniguer logró un aumento del 400% en los ingresos recurrentes anuales y lanzó dos productos aprobados por la FDA. Sus roles ejecutivos anteriores incluyen posiciones en Riverain Technologies, Volpara Health, R2 Technology, Stereotaxis y GE Healthcare.
En su nuevo rol en iCAD, proveedor de soluciones de salud mamaria impulsadas por IA, Koeniguer se centrará en el crecimiento de ingresos en América del Norte y a nivel global, aprovechando su amplia experiencia en el campo de la imagen médica y el software como dispositivo médico (SaMD).
iCAD (NASDAQ: ICAD)는 Mark Koeniguer를 최고 상업 책임자(CCO)로 임명하여 글로벌 성장 이니셔티브를 주도하게 합니다. Koeniguer는 MedTech, AI 및 디지털 헬스 분야에서 30년 이상의 경험을 보유하고 있으며, 상업 판매 팀, 파트너십, 운영 및 고객 성공을 감독할 것입니다.
최근 ScreenPoint Medical의 CEO로서 Koeniguer는 연간 반복 수익을 400% 증가시키고 FDA에서 승인된 두 개의 제품을 출시했습니다. 그의 이전 임원 경력에는 Riverain Technologies, Volpara Health, R2 Technology, Stereotaxis 및 GE Healthcare에서의 직책이 포함됩니다.
iCAD에서의 새로운 역할에서, AI 기반 유방 건강 솔루션 제공업체인 Koeniguer는 북미 및 전 세계에서 수익 성장에 집중하며, 의료 이미징 분야와 의료 기기 소프트웨어(SaMD) 분야에서의 광범위한 경험을 활용할 것입니다.
iCAD (NASDAQ: ICAD) a nommé Mark Koeniguer au poste de Chief Commercial Officer (CCO) pour diriger les initiatives de croissance mondiale. Koeniguer, qui possède plus de 30 ans d'expérience dans le MedTech, l'IA et la santé numérique, supervisera les équipes de vente commerciales, les partenariats, les opérations et la réussite client.
Récemment, en tant que PDG de ScreenPoint Medical, Koeniguer a réalisé une augmentation de 400% des revenus récurrents annuels et a lancé deux produits approuvés par la FDA. Ses précédents postes de direction incluent des rôles chez Riverain Technologies, Volpara Health, R2 Technology, Stereotaxis et GE Healthcare.
Dans son nouveau rôle chez iCAD, fournisseur de solutions de santé mammaire alimentées par l'IA, Koeniguer se concentrera sur la croissance des revenus en Amérique du Nord et à l'échelle mondiale, tirant parti de son expérience approfondie dans le domaine de l'imagerie médicale et des logiciels en tant que dispositif médical (SaMD).
iCAD (NASDAQ: ICAD) hat Mark Koeniguer zum Chief Commercial Officer (CCO) ernannt, um die globalen Wachstumsinitiativen zu leiten. Koeniguer bringt über 30 Jahre Erfahrung im MedTech-, KI- und digitalen Gesundheitsbereich mit und wird die kommerziellen Vertriebsteams, Partnerschaften, den Betrieb und den Kundenerfolg überwachen.
Zuletzt als CEO von ScreenPoint Medical erzielte Koeniguer einen Anstieg des jährlichen wiederkehrenden Umsatzes um 400% und brachte zwei von der FDA genehmigte Produkte auf den Markt. Seine vorherigen Führungspositionen umfassen Positionen bei Riverain Technologies, Volpara Health, R2 Technology, Stereotaxis und GE Healthcare.
In seiner neuen Rolle bei iCAD, einem Anbieter von KI-gestützten Lösungen für die Brustgesundheit, wird Koeniguer sich auf das Umsatzwachstum in Nordamerika und weltweit konzentrieren und dabei seine umfangreiche Erfahrung im Bereich der medizinischen Bildgebung und der Software als Medizinprodukt (SaMD) nutzen.
- Appointment of experienced executive with proven track record of 400% revenue growth
- New CCO brings extensive expertise in medical imaging and AI-powered solutions
- Strong background in successful FDA product launches and commercialization
- Extensive industry network from previous roles at major healthcare companies
- None.
NASHUA, N.H., April 08, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) ("iCAD" or the "Company") a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast health solutions, today announced the appointment of Mark Koeniguer as Chief Commercial Officer (CCO), to lead the next phase of global growth for iCAD.
As CCO at iCAD, Koeniguer will assume responsibilities for revenue growth across North America and around the globe, bringing with him extensive executive experience in the medical imaging field and software as a medical device (SaMD) space. In his new role, Mark will have oversight of the commercial sales teams, partnerships, operations and customer success.
Mark Koeniguer brings more than 30 years of experience leading and scaling MedTech, AI, and digital health companies to iCAD. Most recently, he served as CEO of ScreenPoint Medical, where he transformed the company from a science-led organization into a global commercial enterprise, increasing annual recurring revenue by
Dana Brown, President and CEO of iCAD commented, “Mark’s deep expertise in the radiological health market and AI-powered solutions makes him an ideal leader for this new role. As Chief Commercial Officer, he will be instrumental in positioning iCAD to better engage with global health providers seeking enterprise-wide solutions that elevate both clinical workflows and patient experiences. We are excited to welcome Mark to the team as we continue advancing our mission to transform breast cancer detection.”
“Mark brings extensive industry experience in breast health, diagnostics, and medical solutions from his previous leadership roles at ScreenPoint, Volpara, and GE Healthcare, and his technical understanding of imaging workflows and partner-oriented consultative approach make him well-suited to fuel iCAD’s continued growth,” said Michelle Strong, Chief Operations Officer of iCAD. “We are thrilled to welcome Mark to iCAD where he can be influential in bringing iCAD’s AI-powered suite of ProFound breast cancer detection and risk assessment solutions to more women, everywhere, helping create a world where cancer can’t hide.”
About iCAD, Inc.
iCAD, Inc. (NASDAQ: ICAD) is a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes. Headquartered in Nashua, N.H., iCAD’s industry-leading ProFound Breast Health Suite provides AI-powered mammography analysis for breast cancer detection, density assessment and risk evaluation. Used by thousands of providers serving millions of patients, ProFound is available in over 50 countries. In the last five years alone, iCAD estimates reading more than 40 million mammograms worldwide, with nearly
Forward-Looking Statements
Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about the expansion of access to the Company’s products, improvement of performance, acceleration of adoption, expected benefits of ProFound AI®, the benefits of the Company’s products, and future prospects for the Company’s technology platforms and products. Such forward-looking statements involve a number of known and unknown risks, uncertainties, and other factors that may cause the actual results, performance, or achievements of the Company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited, to the Company’s ability to achieve business and strategic objectives, the willingness of patients to undergo mammography screening, whether mammography screening will be treated as an essential procedure, whether ProFound AI will improve reading efficiency, improve specificity and sensitivity, reduce false positives and otherwise prove to be more beneficial for patients and clinicians, the impact of supply and manufacturing constraints or difficulties on our ability to fulfill our orders, uncertainty of future sales levels, to defend itself in litigation matters, protection of patents and other proprietary rights, product market acceptance, possible technological obsolescence of products, increased competition, government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe,” “demonstrate,” “intend,” “expect,” “estimate,” “will,” “continue,” “anticipate,” “likely,” “seek,” and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at http://www.icadmed.com and on the SEC’s website at http://www.sec.gov.
CONTACTS
Media Inquiries:
pr@icadmed.com
Investor Inquiries:
John Nesbett/Rosalyn Christian
IMS Investor Relations
icad@imsinvestorrelations.com
FAQ
What experience does Mark Koeniguer bring to his new CCO role at ICAD?
What will be Mark Koeniguer's main responsibilities as CCO of ICAD?
What were Mark Koeniguer's achievements at ScreenPoint Medical before joining ICAD?
Which companies has Mark Koeniguer worked for prior to joining ICAD?
